Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    MS201943
Previous Study | Return to List | Next Study

Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03704467
Recruitment Status : Recruiting
First Posted : October 12, 2018
Last Update Posted : May 31, 2019
Sponsor:
Collaborator:
Merck KGaA, Darmstadt, Germany
Information provided by (Responsible Party):
EMD Serono ( EMD Serono Research & Development Institute, Inc. )

Brief Summary:
The study is to evaluate the efficacy and safety of avelumab in combination with M6620 + carboplatin in participants with PARPi-resistant, recurrent, platinum sensitive ovarian, primary peritoneal, or fallopian tube cancer.

Condition or disease Intervention/treatment Phase
Ovarian Cancer Drug: M6620 Drug: Avelumab Drug: Carboplatin Drug: Paclitaxel Drug: Gemcitabine Drug: Bevacizumab Drug: Pegylated Liposomal Doxorubicin (PLD) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 81 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib Safety Run-in and Randomized Phase II, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination With Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants With PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Actual Study Start Date : March 4, 2019
Estimated Primary Completion Date : November 30, 2020
Estimated Study Completion Date : November 24, 2021


Arm Intervention/treatment
Experimental: Carboplatin + M6620 + Avelumab (Part A, Part B)
Part A: Participants will receive avelumab and carboplatin followed by M6620 as a safety run in cohort (non-randomized); Part B participants will be randomized to receive avelumab and carboplatin followed by M6620 (dose-expansion phase II).
Drug: M6620
Part A: Participants will be administered M6620 90 milligram per square meter (mg/m^2) intravenously (IV) on Day 2 of every 3 weeks (Q3W) cycle for a maximum of 6 cycles in combination treatment with carboplatin and avelumab on Day 1. The M6620 dose may be de-escalated to 60 mg/m^2, or 40 mg/m^2. Part B: Participants will be administered M6620 at a dose as confirmed by the safety monitoring committee after the safety run-in (Part A).

Drug: Avelumab
Part A and B: Participants will be administered IV infusion of avelumab 1600 mg on Day 1 of each Q3W cycle for maximum of 6 cycles in combination treatment with carboplatin and M6620 followed by avelumab 800 mg IV on Day 1 of every two weeks (Q2W) cycle as maintenance monotherapy after the last dose of carboplatin and M6620 until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.

Drug: Carboplatin

Part A and B (Experimental): Participants will be administered carboplatin area under the concentration-time curve 5 on Day 1 of each Q3W cycle for a maximum of 6 cycles in combination treatment with avelumab and M6620.

Part B (SoC): Participants will be administered carboplatin intravenously (IV) area under the concentration-time curve (AUC) 5 (+ paclitaxel) or AUC 4 (+ gemcitabine) as a standard of care (SoC) treatment on Day 1 of each Q3W or every 4 weeks (Q4W) cycle for a maximum of 6 cycles, with or without bevacizumab.


Active Comparator: Standard of care (SoC) treatment (Part B)
Part B participants will be randomized to receive standard of care chemotherapy (Investigator choice of 2 options).
Drug: Carboplatin

Part A and B (Experimental): Participants will be administered carboplatin area under the concentration-time curve 5 on Day 1 of each Q3W cycle for a maximum of 6 cycles in combination treatment with avelumab and M6620.

Part B (SoC): Participants will be administered carboplatin intravenously (IV) area under the concentration-time curve (AUC) 5 (+ paclitaxel) or AUC 4 (+ gemcitabine) as a standard of care (SoC) treatment on Day 1 of each Q3W or every 4 weeks (Q4W) cycle for a maximum of 6 cycles, with or without bevacizumab.


Drug: Paclitaxel
Part B: Participants will be administered Paclitaxel 175 mg/m^2 IV on Day 1 Q3W in combination with carboplatin for 6 cycles, with or without bevacizumab.

Drug: Gemcitabine
Part B: Participants will be administered Gemcitabine 1000 mg/m^2 IV on Day 1 and 8 of each Q3W cycle in combination with carboplatin for a maximum of 6 cycles.

Drug: Bevacizumab
Part B: Participants will be administered bevacizumab 15 milligram per kilogram (mg/kg) IV on Day 1 of each Q3W cycle in combination with carboplatin/paclitaxel or carboplatin/gemcitabine followed by bevacizumab monotherapy until disease progression.

Drug: Pegylated Liposomal Doxorubicin (PLD)
Participants will be administered PLD 30 mg/m^2 Q4W in combination with carboplatin for a maximum of 6 cycles with or without bevacizumab.




Primary Outcome Measures :
  1. Part A: Occurrence of Dose-limiting Toxicities (DLTs) During the DLT Observation Period [ Time Frame: Up to 3 weeks ]
  2. Part B: Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors version (RECIST) v1.1 [ Time Frame: Up to 3 years ]

Secondary Outcome Measures :
  1. Part A: Occurrence of Treatment-emergent Adverse Events (TEAEs) and Treatment-related Adverse Events (AEs) According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) [ Time Frame: Up to 3 years ]
  2. Part A and B: Number of Participants With Confirmed Best Overall Response (BOR) [ Time Frame: Up to 3 years ]
  3. Part A and B: Progression-free survival (PFS) [ Time Frame: Up to 3 years ]
  4. Part A and B: Duration of response (DOR) [ Time Frame: Up to 3 years ]
  5. Part A and B: Time to progression (TTP) [ Time Frame: Up to 3 years ]
  6. Part A and B: Time to first subsequent therapy (TFST) [ Time Frame: Up to 3 years ]
  7. Part A and B: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of M6620 and Avelumab [ Time Frame: Pre-dose, 0, 1, 2, 3 and 6 hours post-dose on Day 2 Cycle 1; post-dose 47 hours on Day 4 Cycle 1; pre-dose and at 0 hour on Day 2 Cycle 2 (each Cycle is 21 days) ]
  8. Part A and B: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of M6620 and Avelumab [ Time Frame: Pre-dose, 0, 1, 2, 3 and 6 hours post-dose on Day 2 Cycle 1; post-dose 47 hours on Day 4 Cycle 1; pre-dose and at 0 hour on Day 2 Cycle 2 (each Cycle is 21 days) ]
  9. Part A and B: Area Under the Concentration-time Curve (AUC) of M6620 and Avelumab Over the Dosing Interval From Time Zero to Tau hour [ Time Frame: Pre-dose, 0, 1, 2, 3 and 6 hours post-dose on Day 2 Cycle 1; post-dose 47 hours on Day 4 Cycle 1; pre-dose and at 0 hour on Day 2 Cycle 2 (each Cycle is 21 days) ]
  10. Part A and B: Terminal Rate Constant (λz) of M6620 and Avelumab [ Time Frame: Pre-dose, 0, 1, 2, 3 and 6 hours post-dose on Day 2 Cycle 1; post-dose 47 hours on Day 4 Cycle 1; pre-dose and at 0 hour on Day 2 Cycle 2 (each Cycle is 21 days) ]
  11. Part A and B : Maximum Observed Drug Concentration (Cmax) of M6620 and Avelumab [ Time Frame: Pre-dose, 0, 1, 2, 3 and 6 hours post-dose on Day 2 Cycle 1; post-dose 47 hours on Day 4 Cycle 1; pre-dose and at 0 hour on Day 2 Cycle 2 (each Cycle is 21 days) ]
  12. Part A: Minimum Observed Drug Concentration (Cmin) of M6620 and Avelumab [ Time Frame: Pre-dose, 0, 1, 2, 3 and 6 hours post-dose on Day 2 Cycle 1; post-dose 47 hours on Day 4 Cycle 1; pre-dose and at 0 hour on Day 2 Cycle 2 (each Cycle is 21 days) ]
  13. Part A and B: Time to Reach the Maximum Plasma Concentration (tmax) of M6620 and Avelumab [ Time Frame: Pre-dose, 0, 1, 2, 3 and 6 hours post-dose on Day 2 Cycle 1; post-dose 47 hours on Day 4 Cycle 1; pre-dose and at 0 hour on Day 2 Cycle 2 (each Cycle is 21 days) ]
  14. Part A and B: Apparent Terminal Half-life (t1/2) of M6620 and Avelumab [ Time Frame: Pre-dose, 0, 1, 2, 3 and 6 hours post-dose on Day 2 Cycle 1; post-dose 47 hours on Day 4 Cycle 1; pre-dose and at 0 hour on Day 2 Cycle 2 (each Cycle is 21 days) ]
  15. Part B: Occurrence of TEAEs and Treatment-related AEs and Immune-related Adverse Events (irAEs) According to NCI-CTCAE [ Time Frame: Up to 3 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female participants with recurrent epithelial ovarian cancer who have disease progression following maintenance treatment with a PARPi as defined below:

    1. Participant must have histologically diagnosed epithelial ovarian, primary peritoneal, or fallopian tube cancer, with nonmucinous histology
    2. Participants must have completed at least 2 previous courses of platinum containing therapy (for example, carboplatin or cisplatin) and had documented response (complete response [CR] or partial response [PR]) to the last platinum-based treatment prior to treatment with a PARPi
    3. Participant has received the last dose of platinum-containing treatment at least 6 months prior to study enrollment
    4. Participant has documented disease progression (radiological) after at least 4 months of maintenance treatment with PARPi following a response to platinum-based chemotherapy.
  • Confirmed breast cancer gene (BRCA) 1/2 mutation status or agree to its testing on samples collected in the study.
  • Available formalin-fixed, paraffin-embedded (FFPE) tumor biopsies.
  • Part A: Optional 2 paired on-treatment biopsies on Day 2 of Cycle 1 (first biopsy) and Day 2 of Cycle 1 or Cycle 2 (second biopsy) respectively, before and after M6620 administration, if assessed as feasible at low risk by the interventional radiologist.
  • Part B: Histological tissue specimen (tissue block or 8 to 10 unstained slides) must be available. An archival tumor biopsy is acceptable if obtained after the last progression on PARPi treatment and is less than 4 months old. Otherwise, participants must be willing to undergo mandatory biopsy during the Screening Period to obtain sufficient tissue for histological assessment. Participants need to have an attempted biopsy. However, participants who have measurable disease documented by a radiologist as not feasible or safe to be biopsied are eligible to enter the study
  • Measurable disease according to RECIST v1.1.
  • Other protocol defined inclusion criteria could apply

Exclusion Criteria:

  • Treatment with a nonpermitted drug/intervention as listed below:

    1. Concurrent anticancer treatment (e.g., cytoreductive therapy, radiotherapy, immune therapy, cytokine therapy, monoclonal antibody, or targeted small molecule therapy) or any study intervention within 4 weeks prior to start of study intervention, or not recovered from AEs related to such therapies
    2. History of prior dose reductions or dose interruptions while receiving cisplatin or carboplatin due to toxicity from the platinum or intolerance to either agent, unless discussed with and approved by the Sponsor Medical Monitor
    3. Prior treatment with a PD-1/PD-L1 targeting agent
  • Current use of the following medications at the time of enrollment:

    1. Immunotherapy or immunosuppressive drugs at the time of enrollment (for example (e.g.,) chemotherapy or systemic corticosteroids) EXCEPT for (a) intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra articular injection), (b) systemic corticosteroids at physiologic doses less than or equals to (≤) 10 milligram per day (mg/day) of prednisone or equivalent, (c) steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)
    2. Growth factors EXCEPT where indicated for treatment of study intervention related myelosuppression and for prophylaxis of repeat myelosuppression after initial occurrence
    3. Herbal remedies with immunostimulating properties (e.g., mistletoe extract) or known to potentially interfere with major organ function (e.g., hypericin)
    4. Other DNA damage repair inhibitors (except PARPi) (e.g., inhibitors of ATR, ataxia telangiectasia mutated [ATM] kinase, DNA-dependent protein kinase [DNA-PK], or Wee kinases).
  • Other protocol defined exclusion criteria could apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03704467


Contacts
Layout table for location contacts
Contact: US Medical Information 888-275-7376 service@emdgroup.com
Contact: Communication Center +49 6151 72 5200 service@emdgroup.com

  Show 37 Study Locations
Sponsors and Collaborators
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany
Investigators
Layout table for investigator information
Study Director: Medical Responsible Merck KGaA, Darmstadt, Germany

Layout table for additonal information
Responsible Party: EMD Serono Research & Development Institute, Inc.
ClinicalTrials.gov Identifier: NCT03704467     History of Changes
Other Study ID Numbers: MS201943_0029
2018-001534-17 ( EudraCT Number )
First Posted: October 12, 2018    Key Record Dates
Last Update Posted: May 31, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by EMD Serono ( EMD Serono Research & Development Institute, Inc. ):
Avelumab
Carboplatin
Primary Peritoneal Cancer
Fallopian Tube Cancer
Platinum sensitive ovarian cancer
Deoxy ribonucleic acid (DNA)-damage response inhibition

Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Fallopian Tube Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Fallopian Tube Diseases
Paclitaxel
Albumin-Bound Paclitaxel
Gemcitabine
Bevacizumab
Carboplatin
Doxorubicin
Liposomal doxorubicin
Antibodies, Monoclonal
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators